Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

Journal of Clinical Pathology

Volumn 67, Issue 9, 2014, Pages 772-776

  Ross, Jeffrey S ^a,b   Wang, K ^b   Elkadi, O R ^a   Tarasen, A ^a   Foulke, L ^a   Sheehan, C E ^a   Otto, G A ^b   Palmer, G ^b   Yelensky, R ^b   Lipson, D ^b   Chmielecki, J ^b   Ali, S M ^b   Elvin, J ^b   Morosini, D ^b   Miller, V A ^b   Stephens, P J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CCND1 GENE; DNA SEQUENCE; EGFR GENE; EPHA3 GENE; FEMALE; FGFR1 GENE; GENE; GENE AMPLIFICATION; GENE DELETION; GENOMICS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MCL1 GENE; MLL2 GENE; NF1 GENE; NUCLEIC ACID BASE SUBSTITUTION; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RB1 GENE; RICTOR GENE; TP53 GENE; TSC1 GENE; TUMOR SUPPRESSOR GENE; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SMALL CELL LUNG CARCINOMA; VERY ELDERLY;

TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 84906818599     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202447     Document Type: Article

References (29)

1. Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology 2006;11:241-8.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
3. Sørensen M, Pijls-Johannesma M, Felip E; ESMO Guidelines Working Group. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v120-5.
4. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-55.
5. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43. (Pubitemid 46622112)
6. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
7. Stahel RA, Weber E. Small cell lung cancer: the new biology. Semin Radiat Oncol 1995;5:11-18.
8. D'Angelo SP, Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther 2010;10:1-10.
9. Rosell R, Wannesson L. A genetic snapshot of small cell lung cancer. Cancer Discov 2012;2:769-71.
10. Stovold R, Blackhall F, Meredith S, et al. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer 2012;76:263-8.
11. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
12. Weber JD, Gutmann DH. Deconvoluting mTOR biology. Cell Cycle 2012;11:236-48.
13. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010;29:3733-44.
14. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231-41.
15. Schenone S, Brullo C, Musumeci F, et al. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 2011;18:2995-3014.
16. López-Martin A, Ballestín C, Garcia-Carbonero R, et al. Prognostic value of KIT expression in small cell lung cancer. Lung Cancer 2007;56:405-13. (Pubitemid 46679092)
17. Lu HY, Zhang G, Cheng QY, et al. Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncol Lett 2012;4:89-93.
18. Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008;14:6092-6.
19. Shiao TH, Chang YL, Yu CJ, et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 2011;6:195-8.
20. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev 2013;39:839-50.
21. Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013;8:27-33.
22. Chi A, Remick S, Tse W. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomark Res 2013;1:2.
23. Keating GM. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 2014;74:207-21.
24. Zakowski MF, Ladanyi M, Kris MG. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-15. (Pubitemid 44050422)
25. Lu HY, Wang XJ, Mao WM. Targeted therapies in small cell lung cancer. Oncol Lett 2013;5:3-11.
26. Tsunoda Y, Sakamoto M, Sawada T, et al. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature. Oncology 2011;81:336-44.
27. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-16.
28. Chen S, Xu Y, Chen Y, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE 2012;7:e36326.
29. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76.